INVESTOR RELATIONS Governance Board of Directors At PolarityTE, our board members are selected based on rigorous review. If you are interested in learning more about our process, download the respective documents below. Peter Cohen Chairman of the Board Mr. Cohen previously served on the Board of Directors at the NYSE, as well as previously serving as the CEO and Chairman of the Board of Cowen Inc., Shearson Lehman, and Republic New York Securities. Mr. Cohen is currently a Trustee of Mount Sinai Medical Center, a Member of the Board of Directors of Quadrant Biosciences, Inc., and Vice Chairman and Lead Director of the Board of Directors of Scientific Games Corporation. Additionally, Mr. Cohen has previously served on a number of other corporate and industry boards, including The Federal Reserve International Capital Markets Advisory Committee, American Express, The Depository Trust Company, Telecom Italia SpA, Olivetti SpA, and Kroll Inc. He obtained a Masters of Business Administration from Columbia University in 1969 and a Bachelor of Science from The Ohio State University in 1968. Jessica Shen, MD, MS Director Dr. Jessica Shen possesses extensive clinical development, medical, health economics, regulatory, and quality control experience and worked at Johnson & Johnson from 1999 through 2015 where she was most recently Vice President of Clinical Development and Regulatory Affairs of the Global Surgery Group. Dr. Shen joined Royal Philips in 2015 and currently serves as Senior Vice President, Head of Global Regulatory, Medical, Clinical & Health Economic Outcomes Research (HEOR) Affairs and Global Government Regulations & Standards. In addition to Dr. Shen’s over 20 years of clinical and regulatory experience in roles at Johnson & Johnson, Royal Philips and Abbot Laboratories, she has been credited with a multitude of publications, has helped secure Department of Defense research grants, and has received numerous awards and accolades, including the Johnson Medal (the highest Johnson & Johnson Research and Development award). Dr. Shen obtained her medical degree from Nanjing Medical and a Master of Science from the University of Kentucky, Lexington. Willie Bogan, JD Director Willie Bogan served as Associate General Counsel and Corporate Secretary of McKesson Corporation, a San Francisco-based healthcare services and information technology company, from July 2009 until his retirement in November 2015. He joined McKesson in November 2006 as Associate General Counsel and Assistant Secretary. Before joining McKesson, Mr. Bogan held senior advisory positions at four other public companies in the San Francisco Bay Area – Bank of America, Safeway, Charles Schwab and Catellus Development Corporation. Prior to becoming in-house counsel, he was a partner at Steinberg, Miller, Bogan & Goldstein in Manhattan Beach, California.During his tenure as a business and securities attorney, Mr. Bogan was involved in a variety of substantial commercial transactions and was an advisor to directors and executive management in the boardroom. Through this, Mr. Bogan acquired significant business and financial experience, including in relation to lending, borrowing, hedging, capital deployment, financial results, mergers and acquisitions, risks and risk management. Regarding healthcare, he acquired significant insight into supply chain systems and activities, and into the nature, opportunities and challenges of healthcare technology businesses. Mr. Bogan also has extensive corporate governance experience. Mr. Bogan graduated Phi Beta Kappa and Summa Cum Laude from Dartmouth College, where he majored in Spanish. He earned an MA degree in Politics and Economics from Oxford University, where he studied as a Rhodes Scholar, and a JD degree from Stanford Law School. While at Dartmouth, Mr. Bogan was an All-Ivy, All New-England, All-East and Academic-All American defensive back on the undefeated and nationally ranked 1970 football team and was drafted by the then Baltimore Colts. In addition, he was named a National Football Foundation and Hall of Fame scholar-athlete. In 1989, he was inducted into the Academic All-America Hall of Fame, an honor that recognizes former Academic All-Americans for career achievements. Jeff Dyer, MBA, PhD Director Jeff Dyer is the Horace Beesley professor of strategy at Brigham Young University (BYU), as well as a professor of strategy at the Wharton School, University of Pennsylvania. Before becoming a professor, Mr. Dyer spent five years as a consultant and manager at Bain & Company. His Harvard Press books on innovation, The Innovator's DNA (with Clayton Christensen) and The Innovator's Method are business bestsellers, and his research has been featured in publications such as Forbes, Economist, Fortune, BusinessWeek and the Wall Street Journal. Mr. Dyer is the only strategy scholar in the world to have published at least 6 times in both Harvard Business Review and Strategic Management Journal (the top academic journal in strategy). He was recently ranked #1 on a list of 'most influential management scholars' based upon academic citations and Google searches to his name (among management scholars who received their PhD's after 1990). Mr. Dyer is co-founder of Innovator's DNA LLC, a fast growing innovation consultancy, and has consulted with such companies as Adobe, AT&T, Cisco, Gilead Sciences, Johnson and Johnson, Life Technologies, Magellan Health, Microsoft, NuVasive, and United Technologies. Chris Nolet Director Chris Nolet has served as a director and Chair of the Audit Committee at PolarityTE since April 2020. Mr. Nolet has extensive experience in audit with nearly 40 years in the profession. He is a retired audit partner at Ernst & Young where he was most recently the West Region Life Sciences Industry Leader. Prior to EY, Mr. Nolet spent over twenty years at PricewaterhouseCoopers, where he was a partner and led the North America West Life Sciences Industry Group. Mr. Nolet is currently a member of the Board of Directors of three publicly traded biotechnology companies, Viela Bio, Revance Therapeutics and Jasper Therapeutics, Inc. He is also a member of the Executive Committee and is Co-Chair of the Finance Committee of the California Life Sciences Industry Association (CLSA). Mr. Nolet is a former member of the Finance & Investment Committee and Emerging Companies Section of the Biotechnology Innovation Organization, and he has testified before Congress with Dr. Janet Woodcock, Director of the Center for Drug Evaluation and Research (CDER), regarding the need for FDA reform. Mr. Nolet holds a B.S. in Accounting from San Diego State University and is a Certified Public Accountant in California. David Seaburg Director David Seaburg currently serves as Chair of the Board’s Strategic Review Committee and was previously a director from August 2018 to August 2019. Mr. Seaburg served as PolarityTE’s Chief Executive Officer from April 2020 through August 2021, President of Corporate Development from January 2019 to August 2019. During Mr. Seaburg’s tenure in management, the Company completed several significant restructuring initiatives, primarily focused on reducing costs, enhancing sales of SkinTE® when it was previously marketed as a 361 HCT/P, and preparing PolarityTE for the changes that would be required from a regulatory perspective for SkinTE following the conclusion of FDA’s period of enforcement discretion for 361 HCT/Ps in May 2021. Prior to PolarityTE, Mr. Seaburg spent roughly 25 years of his career at Cowen, Inc., a leading healthcare franchise in equities research, sales and investment banking. He was Managing Director, Head of Sales Trading and a member of the Cowen’s Equity Operating Committee, where he cultivated and led teams operating across multiple disciplines and specialties, leveraging human capital to drive the organization’s success. Over the course of his tenure, he interacted with thousands of healthcare investors and corporate management teams. Mr. Seaburg was also a CNBC Fast Money Contributor, where he provided regular on-air market commentary for the network. Committee Charters Audit Compensation Governance Documents Nominating and Governance Charter Code of Business Ethics and Practices GET EMAIL ALERTS Stay informed about our latest news and updates Sign Up Today > Connect with Us PolarityTE, Inc. on Twitter PolarityTE, Inc. on LinkedIn PolarityTE, Inc. on Facebook PolarityTE, Inc. on YouTube PolarityTE About Platform Investor Relations About Management Team Board of Directors Values News & Media Press Releases Events Conferences Investor Relations Company Info Financial Info SEC Filings Stock Data Governance Contact Scientific Communications Contact Feedback Collaborate Investor Contact HR Report a Concern Careers Current Openings Contact HR © 2017-2021 PolarityTE, Inc. All Rights Reserved. Patents Pending. Privacy Policy PO Terms Distributors Purchase Agreement Terms Disclaimer Sitemap